Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | KYNU | Q16719 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 10/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660607 | 1.00 | FFAR1 (0.45) | FFAR1KYNUCHRM5SLC6A3CTSA | |
| SCHEMBL27810369 | 0.86 | FFAR1 (0.38) | FFAR1KYNUSLC6A3CTSALMNA | |
| SCHEMBL2499306 | 0.86 | FFAR1 (0.38) | FFAR1KYNUSLC6A3CTSALMNA | |
| SCHEMBL27915144 | 0.85 | FFAR1 (0.49) | FFAR1CHRM5SLC6A3CTSAGABBR2 | |
| SCHEMBL14273258 | 0.82 | FFAR1 (0.47) | FFAR1CHRM5SLC6A3GABBR2GABBR1 | |
| SCHEMBL434752 | 0.82 | FFAR1 (0.47) | FFAR1CHRM5SLC6A3GABBR2GABBR1 | |
| SCHEMBL12194206 | 0.82 | CTSA (0.49) | FFAR1CTSALMNA | |
| SCHEMBL2500865 | 0.80 | SMN1; SMN2 (0.60) | FFAR1CHRM5SLC6A3CTSALMNA | |
| SCHEMBL2495385 | 0.80 | SMN1; SMN2 (0.60) | FFAR1CHRM5SLC6A3CTSALMNA | |
| SCHEMBL26629503 | 0.80 | KYNU (0.51) | KYNUSLC6A3CTSAGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205548-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | Amgen, Inc (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009048527-A1 | SUBSTITUTED BIPHENYL GPR40 MODULATORS | AMGEN INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137561-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | FFAR1 18/4885KYNU 3024/4885CHRM5 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.